PhaseV Announces Collaboration with the Crohn's & Colitis Foundation to Advance IBD Research

PhaseV Announces Collaboration with the Crohn's & Colitis Foundation to Advance IBD Research

Collaboration Leverages the Foundation's IBD Plexus® Research Accelerator with PhaseV's AI/ML Solutions to Overcome Key Challenges in Clinical Development and Enhance Personalized Treatment Strategies

Novel Therapies for Inflammatory Bowel Disease

Significant advances in the discovery of novel therapeutic targets for inflammatory bowel disease address a crucial need for patients refractory to availab

Absci Advances Lead AI-Designed Candidate for IBD into the Clinic

Absci, which engineers biologic drugs based on its own generative AI platform, has advanced its lead candidate into the clinic by dosing the first healthy volunteers. The trial is designed to assess the antibody’s ability to treat inflammatory bowel disease (IBD) by targeting tumor necrosis factor-like cytokine 1A (TL1A). The randomized, placebo-controlled Phase I trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and…